Literature DB >> 12860170

Immunization in tumor prevention.

Guido Forni1, Claudia Curcio, Michela Spadaro, John Iliffe, Elena Quaglino, Emma Di Carlo, Piero Musiani, Pier-Luigi Lollini.   

Abstract

Recent experimental data suggest that immunity can be activated to prevent tumors. The rationale for prevention is strong because the setting is one endowed with an immune system that is neither impaired by tumor and treatment-induced suppression, nor tolerant to tumor-associated antigens. Oncogenic growth factor receptors are tumor antigens and rational targets for specific immunoprevention. Successful prevention of mammary carcinomas in Her-2/neu transgenic mice is cited as an evidence of the validity of this approach. The specific properties of the Her-2/neu gene product as an antigen and the nature of the immune responses induced by effective preventive treatments are summarized.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12860170     DOI: 10.1016/S1567-5769(03)00026-2

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  1 in total

1.  Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis.

Authors:  Stefania Croci; Patrizia Nanni; Arianna Palladini; Giordano Nicoletti; Valentina Grosso; Giorgia Benegiamo; Lorena Landuzzi; Alessia Lamolinara; Marianna L Ianzano; Dario Ranieri; Massimiliano Dall'Ora; Manuela Iezzi; Carla De Giovanni; Pier-Luigi Lollini
Journal:  Breast Cancer Res       Date:  2015-05-22       Impact factor: 6.466

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.